Dr. Liu is a partner of Liu Shen & Associates. He is qualified as a patent attorney, attorney-at-law,
M&A dealmaker (intermediate), and IPMS (intellectual property management
system) auditor; and he is a lecturer of the CIPSA (Capital Intellectual
Property Services Association), and also a lecturer of WIP Open Courses by the
Intellectual Property Press.
Dr. Liu focuses
mainly on intellectual property strategic consulting, patent portfolio
management, patent infringement, validity, and freedom-to-operate opinions, and
due diligence; representing many multinational pharmaceutical companies, small
and medium-sized innovative companies in handling intellectual property,
especially in the field of pharmacy, chemistry, material science, chemical
engineering and medical device.
Dr. Liu obtained
his B.S. in Chemistry and Ph.D. in Organic Chemistry, both from Fudan
University (China, 2001 and 2007), and obtained his Master of Laws in
Intellectual Property Law from John Marshall Law School (the U.S., 2016).
Dr. Liu leaded more than 80 non-litigation
IP related cases since 2016. The
technical field includes small molecular pharmaceutical, bio-molecular
pharmaceutical, biosimilar, drug delivery system, polymer and health care
etc.
Representative IP related cases that could
be disclosed include
- IP Due
diligence, in the transaction of. YH25448 against NSCLC from Yuhan Corporation,
for Luoxin Pharma, 2016
- IP Due
diligence, in the license in of NVRX-5133, for C-bridge Capital, 2018
- Freedom-to-operate
opinions on its polymer products and synthesis routs for Sinopec Group,
2017-2019
Dr. Liu participated in almost 20
invalidation/litigation cases in total, including re-examination/invalidation
procedure, first instance, second instance and retrial procedure.
Representative cases that could be
disclosed include
- Boehringer
Ingelheim GmbH (BI, German) v. PRB (China), representing BI in the Beijing Intermediate
court and higher court (2012-2014)
- Boehringer
Ingelheim GmbH (BI, German) v. PRB (China), Third Party: Jiangsu Chia-tai
Tianqing Pharmaceutical Co., Ltd (China), representing BI at the stage of
invalidation and court (the Beijing Intermediate court and higher court as well
as the Supreme Court) procedures (2010-2013)
Presentation that Dr. LIU has publicly made
include
- “IP
Management for Biopharmaceutical company”, Beijing, CHINA, 2020
- “Due diligence of patent”, Beijing,
Shanghai, Suzhou, CHINA, 2019
- “Introduction
of Invalidation in China”, Myers
Wolin, LLC, NJ USA, 2018
- “Patent
Eligible Subject Matter in China”,
Myers
Wolin, LLC, NJ USA, 2018
- “Application
of Doctrine of Equivalence in life cases”, 2017 AIPPI China IP Seminar
- “Sufficient
Disclosure and Support issues in Chinese patent prosecution in chemical and
pharmaceutical areas”, Seminar of Patent Practice in China held by Liu, Shen
& Associates in Chicago of USA, 2015
Publications that Dr. LIU has authored
include
- “Patent
practice: recent developments in life sciences in China”, IAM Life Sciences,
2019, [Co-author]
- “Implications
of recent life sciences cases in China,” IAM Life Sciences, 2017 [Co-author]
- “晶型药物专利在中国的审查及撰写技巧-基于复审、无效、新政诉讼案例实证分析,” Pharm IPR annual forum 2016, [Co-author]
- “Disclosure
Requirements Undergoing Change,” IAM Life Sciences, 2015 [Co-author]
- “China’s
evolving patent system,” AIPLA Daily Report, October 23, 2015 [Co-author]